<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33310">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01703819</url>
  </required_header>
  <id_info>
    <org_study_id>C1201</org_study_id>
    <secondary_id>2012-002358-22</secondary_id>
    <nct_id>NCT01703819</nct_id>
  </id_info>
  <brief_title>Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects</brief_title>
  <acronym>NEUPRO DB</acronym>
  <official_title>Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting - an Explorative Double-blind Study in Healthy Probands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biologische Heilmittel Heel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biologische Heilmittel Heel GmbH</source>
  <oversight_info>
    <authority>Germany: Bundesinstitut für Arzneimittel und Medizinprodukte</authority>
    <authority>Germany: Gesundheitsamt der Landeshauptstadt Duesseldorf, Zentrales lnspektorat fuer klinische Germany: Pruefstellen in Nordrhein-Westfalen Regierungspraesidium Darmstadt, Dezernat ll 23.1</authority>
    <authority>Germany: Regierungspräsidium Karlsruhe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of acutely dosed Neurexan using an
      experimental stress test called the Trier Social Stress Test
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An acute stress reaction is a biopsychological condition arising in response to an event
      which is individually regarded as emotionally stressful. The onset of a stress response is
      associated with specific physiological actions in the sympathetic nervous system, both
      directly and indirectly through the release of adrenaline and to a lesser extent
      noradrenaline from the medulla of the adrenal glands. These catecholamine hormones
      facilitate immediate physical reactions by triggering increases in heart rate and breathing,
      constricting blood vessels. The other major player in the acute stress response is the
      hypothalamic-pituitary-adrenal axis.

      Although stress has been described as a non-specific psychophysiological response to
      environmental stimuli, it is possible to discern specific bodily stress responses caused by
      specific emotional reactions to novel, ambivalent or uncontrollable situations and stimuli.
      For example, social stress induces elevated cortisol levels, particularly if the stressor is
      uncontrollable, unpredictable, and constitutes a social-evaluative threat due to the
      judgment of others  such as in the Trier Social Stress Test. Usually, the TSST induces a
      two-fold increase in saliva cortisol with peaks around 10-20 min. after stress test
      termination. Also, an average increase in heart rates of around 20 beats per minute (bpm) is
      observed during the TSST. In addition, emotional states and feelings have been shown to be
      affected by this stress test, such as marked increases in stress perception,anxiety and
      emotional insecurity  as well as decreases in mood, calmness and feeling awake.

      Preliminary results indicate that Neurexan® may improve coping abilities in stressful
      situations. This study aims to investigate the effect of Neurexan® on subjectively perceived
      nervousness and tension during an acute stressful situation and to characterize the efficacy
      profile of Neurexan®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area under the curve (AUC) of VAS tension values</measure>
    <time_frame>-210 minutes to +100 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) of VAS nervousness values</measure>
    <time_frame>-210 minutes to +100 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in tension and nervousness VAS</measure>
    <time_frame>-180 minutes, -150 minutes, -120 minutes, -90 minutes, -60 minutes, -30 minutes, -15 minutes, 0 minutes, +15 minutes, +30 minutes, +45 minutes, +60 minutes, +75 minutes, +100 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in saliva cortisol and α-amylase</measure>
    <time_frame>-60 minutes, -15 minutes, +15 minutes, +30 minutes, +45 minutes, +60 minutes, +100 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma ACTH, catecholamines, norepinephrine (NE) and epinephrine (E)</measure>
    <time_frame>-60 minutes, +15 minutes, +45 minutes, +100 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Natural Killer (NK) Cells (subgroup)</measure>
    <time_frame>-60 minutes, +15 minutes, +45 minutes, +100 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BP, heart rate and HRV</measure>
    <time_frame>-30 minutes, -15 minutes, 0 minutes, +15 minutes, +30 minutes, +45 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State anxiety and stress perception measured by STAI-X1</measure>
    <time_frame>-90 minutes, +15 minutes, +100 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>-180 minutes to +100 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Acute Stress Reaction</condition>
  <arm_group>
    <arm_group_label>Neurexan®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neurexan®</intervention_name>
    <arm_group_label>Neurexan®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent

          2. Healthy male or female

          3. age between 31 to 59 years

          4. Fluent in German language.

          5. Ability to understand the explanations and instructions given by the study physician

        Exclusion Criteria:

          1. allergies to ingredients of Neurexan® (Passiflora incarnata, Avena sativa, Coffea
             arabica, Zincum isovalerianicum, lactose monohydrate, magnesium stearate) or Placebo

          2. lactose intolerance

          3. use of any psychological stress-management intervention within the last 4 weeks

          4. sick leave for any reason

          5. participation in any other clinical study 3 months prior to Screening Visit

          6. current or recent (3 months prior to Screening Visit) history of substance abuse or
             drug dependence including nicotine and alcohol (as verified in the respective IDCL
             list)

          7. smokers

          8. alcohol intake within last 24 hours (before Baseline Visit V3)

          9. shift workers or work regularly during night time

         10. use of any psychotropic medication or suffering from severe psychiatric illness
             needing acute intervention

         11. BMI &gt; 30 kg/m2

         12. currently pregnant (verified by urine pregnancy test) or lactating

         13. participation in a previous TSST study

         14. high chronic stress as verified with the TICS-SSCS (a score of ≥ 23 on the screening
             scale for chronic stress meets the criterion of being chronically stressed)

         15. major mental disorder as verified with the IDCL (depressive episode, panic disorder,
             social phobia, obsessive-compulsory disorder; alcohol dependency; schizophrenia and
             mania.)

         16. employee of the Sponsor, one of the investigators or the CRO

         17. use of any concomitant medication except contraceptives

         18. any somatic disease or other condition the Investigator or their duly assigned
             representatives believes may affect the ability of the individual to complete the
             study or the interpretation of the study results

         19. Individuals whose ability to speak for themselves lacks or can be doubted
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Schedlowski, Univ.-Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Medizinische Psychologie und Verhaltensimmunbiologie Universitätsklinikum Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut fur Medizinische Psychologie und Verhaltensimmunbiologie Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Psychologie und Psychotherapie</name>
      <address>
        <city>Marburg</city>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007 Jul;87(3):873-904. Review.</citation>
    <PMID>17615391</PMID>
  </reference>
  <reference>
    <citation>Elsenbruch S, Lucas A, Holtmann G, Haag S, Gerken G, Riemenschneider N, Langhorst J, Kavelaars A, Heijnen CJ, Schedlowski M. Public speaking stress-induced neuroendocrine responses and circulating immune cell redistribution in irritable bowel syndrome. Am J Gastroenterol. 2006 Oct;101(10):2300-7. Epub 2006 Sep 4.</citation>
    <PMID>16952284</PMID>
  </reference>
  <reference>
    <citation>Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1-2):76-81.</citation>
    <PMID>8255414</PMID>
  </reference>
  <reference>
    <citation>Schult J, Hero T, Hellhammer J. Effects of powdered fertilized eggs on the stress response. Clin Nutr. 2010 Apr;29(2):255-60. Epub 2009 Oct 17.</citation>
    <PMID>19837490</PMID>
  </reference>
  <reference>
    <citation>Mason JW. A review of psychoendocrine research on the pituitary-adrenal cortical system. Psychosom Med. 1968 Sep-Oct;30(5):Suppl:576-607. Review. PubMed PMID: 4303377.</citation>
    <PMID>4303377</PMID>
  </reference>
  <reference>
    <citation>Weiss JM. Somatic effects of predictable and unpredictable shock. Psychosom Med. 1970 Jul-Aug;32(4):397-408.</citation>
    <PMID>5535207</PMID>
  </reference>
  <reference>
    <citation>Pawlak CR, Jacobs R, Mikeska E, Ochsmann S, Lombardi MS, Kavelaars A, Heijnen CJ, Schmidt RE, Schedlowski M. Patients with systemic lupus erythematosus differ from healthy controls in their immunological response to acute psychological stress. Brain Behav Immun. 1999 Dec;13(4):287-302.</citation>
    <PMID>10600217</PMID>
  </reference>
  <reference>
    <citation>Schedlowski M, Hosch W, Oberbeck R, Benschop RJ, Jacobs R, Raab HR, Schmidt RE. Catecholamines modulate human NK cell circulation and function via spleen-independent beta 2-adrenergic mechanisms. J Immunol. 1996 Jan 1;156(1):93-9.</citation>
    <PMID>8598500</PMID>
  </reference>
  <reference>
    <citation>Schmid-Ott G, Jacobs R, Jäger B, Klages S, Wolf J, Werfel T, Kapp A, Schürmeyer T, Lamprecht F, Schmidt RE, Schedlowski M. Stress-induced endocrine and immunological changes in psoriasis patients and healthy controls. A preliminary study. Psychother Psychosom. 1998;67(1):37-42.</citation>
    <PMID>9491439</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 14, 2013</lastchanged_date>
  <firstreceived_date>October 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute stress reaction</keyword>
  <keyword>stress</keyword>
  <keyword>stress perception</keyword>
  <keyword>physiological stress response</keyword>
  <keyword>Neurexan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Stress</mesh_term>
    <mesh_term>Stress Disorders, Traumatic, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
